Log in
Actimmune May Reduce Fibrosis
Lawrence M. Blatt, Ph.D., InterMune's Senior Vice President of Research had orally reported that "Data presented by our researchers at CHEST provide important insight to the potential anti-fibrotic and anti-inflammatory activity of our two Phase III compounds for IPF, which is characterized by inflammation and fibrosis of the lungs."
Dr. Blatt had further stated that "Our deeper understanding of the molecular pathways affected by our compounds allows us to theorize what the clinical effects may be in patients with treatment, such as potentially improved lung function and slower disease progression."
Interferon Gamma-1b Inhibits Interleukin-4, Endothelin-1, and Transforming Growth Factor-Beta-Induced Up-regulation of Type I Collagen in Cellular Models of Lung Fibrosis.
FDA Approved : Interactive Breathing Device
A Natural, Relaxing and Clinically Proven Way to Manage Blood Pressure
Helps You Breath Easy and Lowers Your Blood Pressure
RESPeRATE